论文部分内容阅读
根据Ｏｋａｍｏｔｏ基因分型法对２８例丙肝患者的病毒基因进行了分型，１８例为ＨＣＶ－Ⅱ型，１０例为ＨＣＶ－Ⅲ型。重点研究了α－２ｂＩＦＮ治疗ＨＣＶ－Ⅱ型患者和ＨＣＶ－Ⅲ型患者免疫功能的不同改变：在α－２ｂＩＦＮ治疗前，ＨＣＶ－Ⅱ型患者和ＨＣＶ－Ⅲ型患者之间ＩｇＧ、ＩｇＭ、ＩｇＡ、ＣＤ４百分比、ＣＤ８百分比及ＣＤ４／ＣＤ８比值６项指标无明显差别。α－２ｂＩＦＮ治疗８ｗ时，ＨＣＶ－Ⅲ型患者ＣＤ４／ＣＤ８比值明显高于ＨＣＶ－Ⅱ型患者ＣＤ４／ＣＤ８比值。α－２ｂＩＦＮ治疗１个疗程（１２ｗ）时，ＨＣＶ－Ⅲ型患者ＣＤ４百分比，ＣＤ４／ＣＤ８比值明显高于ＨＣＶ－Ⅱ型患者。α－２ｂＩＦＮ治疗１个疗程后第４周（１６ｗ）时，ＨＣＶ－Ⅲ型患者ＣＤ４百分比，ＣＤ４／ＣＤ８比值仍明显高于ＨＣＶ－Ⅱ型患者，但在整个治疗过程中，ＨＣＶ－Ⅲ型和Ⅱ型患者ＩｇＧ、ＩｇＭ、ＩｇＡ和ＣＤ８百分比４项指标改变无显著差异。α－２ｂＩＦＮ治疗ＨＣＶ－Ⅲ型患者，其ＣＤ４百分比，ＣＤ４／ＣＤ８比值改变明显高于ＨＣＶ－Ⅱ型患者。这可能是α－２ｂＩＦＮ治疗ＨＣＶ－Ⅲ型患者疗效明显好于ＨＣＶ－Ⅱ型患者重要原因之一。
According to Okamoto genotyping, the viral genes of 28 hepatitis C patients were genotyped, 18 were HCV-II and 10 were HCV-III. The different changes of immune function in α-2bIFN-treated HCV-Ⅱand HCV-Ⅲ patients were mainly studied: IgG, IgM, IgA, CD4 percentage, CD8 percentage and CD4 / CD8 ratio of six indicators no significant difference. The ratio of CD4 / CD8 in patients with HCV-Ⅲ was significantly higher than that in patients with HCV-Ⅱ when treated with α-2bIFN for 8 weeks. The percentage of CD4 and the ratio of CD4 / CD8 in HCV-Ⅲ patients were significantly higher than those in HCV-Ⅱ patients after α-2bIFN treatment for one course of treatment (12 weeks). The CD4 percentage and the CD4 / CD8 ratio in patients with HCV-Ⅲ were significantly higher than those in patients with HCV-Ⅱ at the 4th week (16w) after treatment with α-2bIFN. However, in the whole course of treatment, HCV-Ⅲ and There was no significant difference in the four indicators of type Ⅱ IgG, IgM, IgA and CD8 percentage. α-2bIFN treatment of HCV-Ⅲ type of patients, the percentage of CD4, CD4 / CD8 ratio was significantly higher than HCV-Ⅱ type patients. This may be the α-2bIFN treatment of HCV-Ⅲ type of patients was significantly better than HCV-Ⅱ type of patients one of the important reasons.